Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab +/- Dupilumab in Atopic Dermatitis
NCT03736967Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of itepekimab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Nov 2018; status: terminated.
02
Drugs
itepekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03736967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736967.